Description
+ Include: 28 videos, size: 8.69 GB
+ Target Audience: rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians
+ Sample video: contact me for sample video
+ Information:
Biologic Therapies Summit IX 2021 returns to in-person learning, bringing together world leaders in immune-based therapies and addressing cutting-edge topics in immunology and rheumatology. The course begins with a full day devoted to vasculitis, including key issues in the differential diagnosis of vasculitis, CNS vasculitis, ANCA-associated vasculitis, and organ-specific issues in vasculitis. The Biologic Therapies Summit X offers six sessions over two days, and kicks off with a half-day session featuring talks on CAR T-cell therapy, irAEs, precision medicine and the next generation of JAK inhibitors for IMIDs, and advances in complement biology and therapy. We take a deep dive into rheumatoid arthritis, AS, PsA and SpA in the afternoon. Day two addresses infections, COVID-19, co-morbidities with IMIDs, including ILD and cardiovascular risk in immune-mediated diseases, and lupus. We wrap up the Summit with a session devoted to pain management, as we welcome physician, writer, and clinical researcher, Haider Warraich, MD, for an exploration of the social and scientific fundamentals of pain.
Why Attend?
- Join for a full-day devoted to hot topics in Vasculitis
- Hear from internationally renowned experts in the fields of immunology and rheumatology
- Expand and enhance decision-making skills for appropriate use of biologic therapies in highly complex clinical situations
- Participate in our APP workshop, included with course registration
By Attending, You Will Be Able To:
- Describe and critically appraise the immunologic mechanisms of action for targeted therapies and targeted synthetic therapies as they apply to efficacy and safety across the spectrum of immune-mediated inflammatory diseases including PsA, SpA, RA, SLE and vasculitis.
- Outline how precision medicine has been used to manage immune-related adverse events.
- Define advances in complement with rheumatic and immunologic diseases.
- Summarize evidence on COVID-19 and vaccinations and their effects on patients with immune-mediated inflammatory diseases, and describe the implications for clinical practice.
- Critically appraise how Long COVID presents in patients with immune-mediated inflammatory diseases.
- Evaluate comorbidities such as cardiovascular risk and complications associated with immune-mediated diseases.
- Define the clinical differences between type 1 and type 2 lupus.
Who Should Attend?
The Summit is directed towards rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, pharmacists, nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and autoinflammatory disorders.
+ Topics:
A Vasculitis Case Presentation.mp4
Advances in Pulmonary Aspects of Progressive Systemic Sclerosis.mp4
Advances in understanding of the immunobiology of COVID-19 – at 1.5 years.mp4
Are There Factors That Can Guide Treatment Decisions in Newly Diagnosed and Relapsing Takayasu Arteritis.mp4
Clinical Approach to Diagnosis and Treatment of Cytokine Storm in Rheumatic Diseases.mp4
COVID-19 and Autoimmunity.mp4
Cytokine Storm Where Rheumatologists, Oncologists, and ID Meet.mp4
Difficult Rheumatoid Arthritis.mp4
Does Plasma Exchange Have a Role in Patients With ANCA-Associated Vasculitis and Rapidly Progressive Glomerulonephritis or Pulmonary Hemorrhage.mp4
Endocarditis and the Rheumatologist.mp4
Evolving Treatment Strategies in Psoriatic Arthritis (PsA) How Do We Choose.mp4
How do I Recognize and Treat the VEXAS Syndrome.mp4
How Does the Treatment of Beh‡et’s Disease Differ Based on Disease Manifestations.mp4
Is There Still a Role for Conventional Immunosuppressive Agents in ANCA-Associated Vasculitis.mp4
JAK Inhibitors for Rheumatoid Arthritis Focus on Safety.mp4
Maintenance Rituximab in ANCA-Associated Vasculitis Dose, Frequency, and Duration – How Do We Decide.mp4
MANAGING IMMUNOMODULATING THERAPIES AND IMMUNOCOMPROMISED PATIENTS DURING THE COVlD-l9 PANDEMIC.mp4
Non-Radiographic Axial Spondyloarthritis New Name to an old Disease.mp4
Psoriatic Arthritis- Different treatment responses of skin and joint manifestations.mp4
Safety of Biologics and JAK Inhibitors (Mycobacterial Infections).mp4
Targeted Theories in irAES.mp4
Vaccinating Patients with Immune Mediated Inflammatory Disease.mp4
Vasculitis Treatment Case Presentation.mp4
What Are the Options for Treating CNS Vasculitis.mp4
What Dose and Duration of Glucocorticoids Should be Used in ANCA-Associated Vasculitis.mp4
What’s New in SpA Case Presentation.mp4
When Should Biologic Agents be Considered in Eosinophilic Granulomatosis With Polyangiitis.mp4
When Should Biologic Agents be Introduced in Giant Cell Arteritis and For How Long Should They Be Given.mp4
Reviews
There are no reviews yet.